Related Experiment Video

Updated: Aug 25, 2025

Assaying the Kinase Activity of LRRK2 in vitro
06:09

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

22.6K

MiR-205 Regulates LRRK2 Expression in Dopamine Neurons in Parkinson's Disease through Methylation Modification

Hongwei Wang1, Jie Li1, Liang Tao2

  • 1Department of Neurology, The Second Affiliated Hospital of Qiqihar Medical University, Qiqihar 161006, China.

Iranian Journal of Public Health
|October 17, 2022
PubMed
Abstract

Insights

Methylation of miR-205 promoter is altered in Parkinson's disease (PD) models. This epigenetic modification impacts Leucine-Rich Repeat Kinase 2 (LRRK2) expression, suggesting a novel therapeutic target for PD.

Area of Science:

  • Neuroscience
  • Epigenetics
  • Molecular Biology

Background:

  • Parkinson's disease (PD) involves complex pathological changes.
  • MicroRNA-205 (miR-205) and Leucine-Rich Repeat Kinase 2 (LRRK2) are implicated in PD pathogenesis.
  • Epigenetic modifications, specifically DNA methylation, are increasingly recognized in neurodegenerative diseases.

Purpose of the Study:

  • To investigate the role of miR-205 promoter methylation in Parkinson's disease.
  • To elucidate the regulatory relationship between miR-205 and LRRK2 in PD.
  • To identify potential novel therapeutic targets for PD based on miR-205 methylation.

Main Methods:

  • Quantitative PCR (qPCR) and Western blotting were used to assess miR-205 and LRRK2 expression in PD model cells.
  • Cellular genomic DNA was analyzed for miR-205 promoter methylation using bisulfite treatment.
  • Bioinformatic analysis (TargetScan) predicted miR-205 binding sites in the LRRK2 non-coding region.

Main Results:

  • miR-205 levels were reduced and its promoter hypermethylated in PD model cells (SH-SY5Y).
  • Inhibition of methylation using 5-Azacytidine increased miR-205 levels and decreased LRRK2 expression.
  • Overexpression of miR-205 reduced LRRK2 transcription and translation, confirming a direct regulatory link.

Conclusions:

  • Methylation of the miR-205 promoter epigenetically regulates LRRK2 expression in dopaminergic neurons.
  • miR-205 methylation represents a promising and novel therapeutic target for Parkinson's disease treatment.
Keywords:
Parkinson’s diseaseRNA interferencemiR-205

More Related Videos

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation12:49

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

7.6K
Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag08:55

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag

Published on: December 14, 2017

15.3K

Related Concept Videos

Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.7K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
353
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
671
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
6.9K